These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 28292441)

  • 1. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
    Blattner M; Liu D; Robinson BD; Huang D; Poliakov A; Gao D; Nataraj S; Deonarine LD; Augello MA; Sailer V; Ponnala L; Ittmann M; Chinnaiyan AM; Sboner A; Chen Y; Rubin MA; Barbieri CE
    Cancer Cell; 2017 Mar; 31(3):436-451. PubMed ID: 28292441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in
    Yan Y; An J; Yang Y; Wu D; Bai Y; Cao W; Ma L; Chen J; Yu Z; He Y; Jin X; Pan Y; Ma T; Wang S; Hou X; Weroha SJ; Karnes RJ; Zhang J; Westendorf JJ; Wang L; Chen Y; Xu W; Zhu R; Wang D; Huang H
    EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29523594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
    Geng C; Rajapakshe K; Shah SS; Shou J; Eedunuri VK; Foley C; Fiskus W; Rajendran M; Chew SA; Zimmermann M; Bond R; He B; Coarfa C; Mitsiades N
    Cancer Res; 2014 Oct; 74(19):5631-43. PubMed ID: 25274033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
    Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
    Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
    Shoag J; Liu D; Blattner M; Sboner A; Park K; Deonarine L; Robinson BD; Mosquera JM; Chen Y; Rubin MA; Barbieri CE
    J Clin Invest; 2018 Jan; 128(1):381-386. PubMed ID: 29202479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
    Tan M; Xu J; Siddiqui J; Feng F; Sun Y
    Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
    Yan Y; Huang H
    Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
    Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
    Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
    Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
    Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
    Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
    Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
    Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPOP-mutant prostate cancer: Translating fundamental biology into patient care.
    Bernasocchi T; Theurillat JP
    Cancer Lett; 2022 Mar; 529():11-18. PubMed ID: 34974131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What controls PTEN and what it controls (in prostate cancer).
    Ghosh PM
    Asian J Androl; 2012 Jan; 14(1):130-1. PubMed ID: 21946231
    [No Abstract]   [Full Text] [Related]  

  • 14. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
    Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
    Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity.
    Grbesa I; Augello MA; Liu D; McNally DR; Gaffney CD; Huang D; Lin K; Ivenitsky D; Goueli R; Robinson BD; Khani F; Deonarine LD; Blattner M; Elemento O; Davicioni E; Sboner A; Barbieri CE
    Cell Rep; 2021 Sep; 36(10):109625. PubMed ID: 34496233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of speckle-type POZ protein (SPOP) in cancer development.
    Mani RS
    Drug Discov Today; 2014 Sep; 19(9):1498-502. PubMed ID: 25058385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and genomic features of SPOP-mutant prostate cancer.
    Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
    Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
    Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
    Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
    Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
    Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation.
    Bilir B; Osunkoya AO; Wiles WG; Sannigrahi S; Lefebvre V; Metzger D; Spyropoulos DD; Martin WD; Moreno CS
    Cancer Res; 2016 Mar; 76(5):1112-21. PubMed ID: 26701805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.